| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 250mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
BRD0418 targets the expression of tribbles pseudokinase 1 (TRIB1). By upregulating TRIB1, it modulates the expression of key genes involved in cholesterol and triglyceride biosynthesis, such as LDLR, TRIB1, and PCSK9, as well as VLDL production and LDL uptake in HepG2 cells. This reprogramming of hepatic lipoprotein metabolism from lipogenesis to scavenging is the primary mechanism of action.
|
|---|---|
| ln Vitro |
In vitro, BRD0418 has been shown to modulate the expression of key genes involved in cholesterol and triglyceride biosynthesis in HepG2 cells. It upregulates TRIB1 expression and leads to the reprogramming of hepatic lipoprotein metabolism. These effects are consistent with its potential to treat coronary artery disease.
|
| ln Vivo |
In vivo, BRD0418 is being evaluated for its effects on lipid metabolism and cardiovascular disease. Its ability to reprogram hepatic lipoprotein metabolism makes it a promising candidate for the treatment of dyslipidemia and coronary artery disease.
|
| Enzyme Assay |
In vitro enzyme or receptor binding (non-cell) assays for BRD0418 are less common due to its mechanism of action involving gene expression regulation. However, its effects on the expression of target genes can be studied using reporter gene assays. In these assays, cells are transfected with a luciferase reporter construct containing the promoter of a target gene, and the effect of the compound on reporter activity is measured.
|
| Cell Assay |
In vitro cell-based assays for BRD0418 are performed using HepG2 cells. Cells are treated with the compound, and the expression of TRIB1 and other target genes is measured by qPCR. The effects on lipid metabolism are assessed by measuring cholesterol and triglyceride levels in the cells and media.
|
| Animal Protocol |
In vivo animal experiments for BRD0418 are conducted using mouse models of dyslipidemia and coronary artery disease. The compound is administered, and its effects on plasma lipid levels, hepatic gene expression, and atherosclerotic plaque formation are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of BRD0418 have been characterized to support its use as a research tool. The compound has a molecular weight of 488.57 and a formula of C₂₉H₃₂N₂O₅. It is soluble in DMSO. Specific PK parameters, such as half-life and bioavailability, are determined in preclinical studies via LC-MS/MS analysis of plasma samples.
|
| Toxicity/Toxicokinetics |
Toxicology (toxicology) data for BRD0418 are typical of a research compound. It is generally well-tolerated at effective doses. The safety profile is being evaluated in the context of its use as a research tool to study TRIB1 biology.
|
| Additional Infomation |
2-[(1S,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenoxyphenyl)methyl]acetamide is an aromatic ether.
Other information: BRD0418 is a research compound used to study the role of TRIB1 in lipid metabolism and cardiovascular disease. It is available from chemical suppliers for preclinical research purposes. |
| Molecular Formula |
C29H32N2O5
|
|---|---|
| Molecular Weight |
488.574788093567
|
| Exact Mass |
488.231
|
| CAS # |
1565827-99-7
|
| Related CAS # |
1565827-99-7
|
| PubChem CID |
54646219
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.6
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
36
|
| Complexity |
706
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CN(C)C1=CC2=C(C=C1)O[C@@H]3[C@H]2C[C@H](O[C@H]3CO)CC(=O)NCC4=CC=C(C=C4)OC5=CC=CC=C5
|
| InChi Key |
MRJCPWMBHXTRFB-HGAMEBRSSA-N
|
| InChi Code |
InChI=1S/C29H32N2O5/c1-31(2)20-10-13-26-24(14-20)25-15-23(35-27(18-32)29(25)36-26)16-28(33)30-17-19-8-11-22(12-9-19)34-21-6-4-3-5-7-21/h3-14,23,25,27,29,32H,15-18H2,1-2H3,(H,30,33)/t23-,25-,27-,29+/m0/s1
|
| Chemical Name |
2-((1S,3S,4aS,9aR)-6-(Dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl)-N-(4-phenoxybenzyl)acetamide
|
| Synonyms |
BRD0418 BRD-0418 BRD 0418
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0468 mL | 10.2339 mL | 20.4679 mL | |
| 5 mM | 0.4094 mL | 2.0468 mL | 4.0936 mL | |
| 10 mM | 0.2047 mL | 1.0234 mL | 2.0468 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA